A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)

NCT01104519 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia

Interventions

DRUG: Niaspan
DRUG: Comparator: Placebo

Sponsor

Merck Sharp & Dohme LLC